Literature DB >> 27365781

Biomarkers of malignant ascites-a myth or reality.

Mithu Banerjee1, Rajeshwar Singh2, M M Arora3, V Srinivas4, D Basannar5, Seema Patrikar6.   

Abstract

BACKGROUND: Ascitic fluid aspirate cytology, although reasonably specific is not a good screening tool for malignant ascites due to poor sensitivity. Simple test(s) on ascitic fluid or serum which can help differentiate between benign and malignant causes of ascites will be a boon. Ascitic fluid lactate dehydrogenase, cholesterol, and ferritin are the candidate markers evaluated in this study.
METHODS: Ascitic fluid cytology was done on 30 patients of malignant ascites. The modalities used for diagnosing malignant ascites were positive peritoneal biopsy or CT scan evidence of hepatic metastases. Ascitic fluid biochemistry was done in all these 30 patients as well as 30 cases of non-malignant ascites. The parameters analysed were cholesterol, lactate dehydrogenase, and ferritin. The biochemical parameters were estimated in serum as well.
RESULTS: Cytology had a sensitivity of 40% for the diagnosis of malignant ascites. Ascitic fluid cholesterol, lactate dehydrogenase, and ferritin had sensitivities of 70%, 74%, and 100%, respectively. Serum cholesterol, lactate dehydrogenase, and ferritin had sensitivities of 57%, and 91%, respectively.
CONCLUSION: Hence, these biochemical markers in ascitic fluid as well as serum can be good screening tools for the diagnosis of malignant ascites.

Entities:  

Keywords:  ascites; cholesterol; ferritin; lactate dehydrogenase; malignant

Year:  2011        PMID: 27365781      PMCID: PMC4920757          DOI: 10.1016/S0377-1237(11)60005-1

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  10 in total

1.  Fibronectin, cholesterol and triglycerides ascitic fluid concentration in the prediction of malignancy.

Authors:  G Colloredo Mels; G Bellati; L Auriemma; C Perani; G Leandro; N Vacca; N Pinna; G Alfieri; G Ideo
Journal:  Ital J Gastroenterol       Date:  1991-05

2.  Ascitic fluid concentrations of fibronectin and cholesterol: comparison of differential diagnostic value with the conventional protein determination.

Authors:  A L Gerbes; Y N Xie; J Mezger; D Jüngst
Journal:  Liver       Date:  1990-06

3.  Diagnostic value of ascitic fluid cholesterol levels in the prediction of malignancy.

Authors:  P B Mortensen; S D Kristensen; A Bloch; B A Jacobsen; S N Rasmussen
Journal:  Scand J Gastroenterol       Date:  1988-11       Impact factor: 2.423

4.  Diagnostic value of ascitic fluid lactic dehydrogenase, protein, and WBC levels.

Authors:  T D Boyer; A M Kahn; T B Reynolds
Journal:  Arch Intern Med       Date:  1978-07

5.  The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions.

Authors:  D Sears; S I Hajdu
Journal:  Acta Cytol       Date:  1987 Mar-Apr       Impact factor: 2.319

6.  Ascitic fluid analysis for the differentiation of malignancy-related and nonmalignant ascites. Proposal of a diagnostic sequence.

Authors:  A L Gerbes; D Jüngst; Y N Xie; W Permanetter; G Paumgartner
Journal:  Cancer       Date:  1991-10-15       Impact factor: 6.860

7.  Diagnosis of malignant ascites. Comparison of ascitic fibronectin, cholesterol, and serum-ascites albumin difference.

Authors:  M Prieto; M J Gómez-Lechón; M Hoyos; J V Castell; D Carrasco; J Berenguer
Journal:  Dig Dis Sci       Date:  1988-07       Impact factor: 3.199

8.  Malignant ascites. Clinical and experimental observations.

Authors:  R N Garrison; L D Kaelin; R H Galloway; L S Heuser
Journal:  Ann Surg       Date:  1986-06       Impact factor: 12.969

9.  Value of ascitic fluid ferritin in the differential diagnosis of malignant ascites.

Authors:  J Kountouras; P Boura; G Tsapas; K Charisis; I Magoula; I Tsakiri
Journal:  Anticancer Res       Date:  1993 Nov-Dec       Impact factor: 2.480

10.  Total discrimination of peritoneal malignant ascites from cirrhosis- and hepatocarcinoma-associated ascites by assays of ascitic cholesterol and lactate dehydrogenase.

Authors:  G Castaldo; G Oriani; L Cimino; M Topa; I Mostarda; L Castellano; C Del Vecchio-Blanco; G Budillon; F Salvatore; L Sacchetti
Journal:  Clin Chem       Date:  1994-03       Impact factor: 8.327

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.